Johnson ZL , Lee JH , Lee K , Lee M , Kwon DY , Hong J , Lee SY .

R01 GM100984 NIGMS NIH HHS , R01GM100984 NIGMS NIH HHS

	Figure 1. The nucleoside-binding site of vcCNT and fluorescence-anisotropy-based competition assay.(A) The vcCNT-7C8C trimer viewed from within the plane of the membrane. The location of the membrane is marked by rectangles. The scaffold domain of one protomer is colored light blue, and the transport domain is colored red, blue, orange, cyan, wheat, and brown. The other two protomers are colored gray. Uridine is shown bound to each protomer in stick representation. The nucleoside-binding site is delineated with dashed lines. vcCNT-7C8C functions similarly to wild type (Figure 1—figure supplement 1). (B) The vcCNT-7C8C protomer. The structure is rotated 120° about the trimer axis relative to A, zoomed in, and the other two protomers have been removed for clarity. (C) Nucleoside-binding site. Amino acid residues that interact with the uridine are labeled and shown in stick representation and were used for sequence identity calculation with hCNTs. Hydrogen bonds are shown as dashed lines. The uracil base is marked with a blue box, and the ribose is marked with a gray box. For a stereo view of the electron density in the nucleoside-binding site, see Figure 1—figure supplement 2. (D) Fluorescence titration of vcCNT with uridine. Uridine was titrated into solution containing vcCNT and the fluorescent nucleoside pyrrolo-cytidine, anisotropy was measured, and data were fit to a single-site competitive binding model to obtain a KD of 36 ± 3 μM (mean ± SEM, n = 3 measurements).DOI: http://dx.doi.org/10.7554/eLife.03604.003Figure 1—figure supplement 1. vcCNT-7C8C maintains nucleoside transport activity.Wild-type (WT) and 7C8C vcCNT were reconstituted into lipid vesicles and assessed for their ability to support the uptake of 2 μM of 3H-labeled nucleosides as described (Johnson et al., 2012). The data shown represent 2 min timepoints. Empty vesicles were included as a negative control.DOI: http://dx.doi.org/10.7554/eLife.03604.004
	Figure 1—figure supplement 2. Electron density at the nucleoside-binding site of vcCNT-7C8C-uridine.The nucleoside-binding site of vcCNT-7C8C bound to uridine is shown in stereo in stick representation in the same orientation and colored as in Figure 1C. Uridine is yellow and the red spheres are water molecules. The resolution is 2.1 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.005
	Figure 2. Structural basis of nucleobase recognition by vcCNT.(A) The crystal structure of vcCNT bound to zebularine. (B) Chemical structure of 3-methyluridine. (C) The crystal structure of vcCNT-7C8C bound to adenosine. (D) The crystal structure of vcCNT-7C8C bound to ribavirin. (E) The crystal structure of vcCNT-7C8C bound to 5-fluorouridine. Fluorine is colored cyan. All electron density maps represent Fo–Fc SA-OMIT maps for the nucleoside contoured at 3σ. Uridine is shown in the center of the figure for reference. For stereo views of the electron density in the nucleoside-binding site for each of these structures, see Figure 2—figure supplements 1–4.DOI: http://dx.doi.org/10.7554/eLife.03604.009Figure 2—figure supplement 1. Electron density at the nucleoside-binding site of vcCNT-zebularine.The nucleoside-binding site of vcCNT bound to zebularine is shown in stereo in stick representation in the same orientation and colored as in Figure 2A. Zebularine is yellow and the red spheres are water molecules. The resolution is 2.9 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.010
	Figure 2—figure supplement 2. Electron density at the nucleoside-binding site of vcCNT-7C8C-adenosine.The nucleoside-binding site of vcCNT-7C8C bound to adenosine is shown in stereo in stick representation in the same orientation and colored as in Figure 2C. Adenosine is yellow and the red sphere is a water molecule. The resolution is 3.1 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.011
	Figure 2—figure supplement 3. Electron density at the nucleoside-binding site of vcCNT-7C8C-ribavirin.The nucleoside-binding site of vcCNT-7C8C bound to ribavirin is shown in stereo in stick representation in the same orientation and colored as in Figure 2D. Ribavirin is yellow and the red sphere is a water molecule. The resolution is 2.8 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.012
	Figure 2—figure supplement 4. Electron density at the nucleoside-binding site of vcCNT-7C8C-5-fluorouridine.The nucleoside-binding site of vcCNT-7C8C bound to 5-fluorouridine is shown in stereo in stick representation in the same orientation and colored as in Figure 2E. 5-fluorouridine is yellow and the red spheres are water molecules. The resolution is 2.3 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.013
	Figure 3. Phe 366 is crucial for nucleoside binding by vcCNT.(A) The nucleoside-binding site of vcCNT-7C8C bound to uridine is shown viewed from the cytoplasm. Phe 366 interacts with the uracil base via π–π interactions. The other epimeric 2′ position is marked with an arrow. (B) Another view of the interaction between Phe 366 and uridine. Phe 366 interacts with the ribose via CH–π interactions (dashed lines). (C–F) Isothermal titration calorimetry of uridine binding to wild-type vcCNT and Phe 366 mutants. KD = 45 ± 8 μM and ΔHo = −2970 ± 330 cal/mol for WT, KD = 1630 ± 120 μM and ΔHo = −2200 ± 190 cal/mol for F366A, KD = 920 ± 170 μM and ΔHo = −1600 ± 440 cal/mol for F366Y, and KD = 1470 ± 90 μM and ΔHo = −3190 ± 130 cal/mol for F366W (means ± SEM, n = 3 measurements). Note that the KD for F366A could not be reliably measured due to the low heat associated with binding. Each of the F366 mutants is biochemically stable as evidenced by a single, sharp peak at the expected trimer size when subjected to size-exclusion chromatography (Figure 3—figure supplement 1).DOI: http://dx.doi.org/10.7554/eLife.03604.015Figure 3—figure supplement 1. F366 mutants are biochemically stable.1 liter of each construct was expressed and purified in parallel without the addition of any exogenous nucleosides as described in the ‘Materials and methods’. Each sample was initially purified by size-exclusion chromatography using a Superdex 200 10/300 GL column to remove MBP, and then the peak fractions were collected, concentrated, and re-ran to generate the figures. Each individual chromatogram is shown in the top panels with absolute absorbance at 280 nm on the y-axis, and all of the normalized chromatograms are shown overlaid in the bottom panel.DOI: http://dx.doi.org/10.7554/eLife.03604.016
	Figure 4. Structural basis of ribose recognition by vcCNT.(A) Dissociation constants for deoxyuridines. (B) Chemical structures and KDs of cytidine, gemcitabine, and cytarabine. The cytidine is from the crystal structure of vcCNT-7C8C bound to cytidine (for a stereo view of the electron density in the nucleoside-binding site of this structure, see Figure 4—figure supplement 1), and the other nucleosides are simply chemical structures in the same orientation as cytidine. Fluorine atoms in gemcitabine are colored cyan. (C) Crystal structure of vcCNT-7C8C bound to gemcitabine. Density shown is from an Fo–Fc SA-OMIT map contoured at 3σ. For a stereo view of the electron density in the nucleoside-binding site, see Figure 4—figure supplement 2. (D) Alignment of uridine-bound and gemcitabine-bound vcCNT structures. Structures were aligned by Cα using PyMOL. TM7 was not used for the alignment. Cα traces and interacting amino acid residues are shown. The uridine-bound vcCNT structure (PDB ID: 3TIJ) is gray and the gemcitabine-bound vcCNT-7C8C structure is deep purple. (E) Alignment of vcCNT and vcCNT-7C8C structures bound to uridine (PDB ID: 3TIJ), zebularine, cytidine, pyrrolo-cytidine, 5-fluorouridine, and gemcitabine. Alignments were performed in the same manner as D. vcCNT-7C8C-gemcitabine is shown in hot pink and all other structures are shown in gray.DOI: http://dx.doi.org/10.7554/eLife.03604.017Figure 4—figure supplement 1. Electron density at the nucleoside-binding site of vcCNT-7C8C-cytidine.The nucleoside-binding site of vcCNT-7C8C bound to cytidine is shown in stereo in stick representation in the same orientation and colored as the structures in Figure 2. Cytidine is yellow and the red spheres are water molecules. The resolution is 2.6 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.018
	Figure 4—figure supplement 2. Electron density at the nucleoside-binding site of vcCNT-7C8C-gemcitabine.The nucleoside-binding site of vcCNT-7C8C bound to gemcitabine is shown in stereo in stick representation in the same orientation and colored as in Figure 4C. Gemcitabine is yellow and the red sphere is a water molecule. The resolution is 2.9 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.019
	Figure 5. Design of pyrrolo-gemcitabine and its transportability by hCNTs.(A) Chemical structures and KDs of gemcitabine and the pyrrolo-nucleosides. (B) The crystal structure of vcCNT-7C8C in complex with pyrrolo-cytidine is shown in surface representation with pyrrolo-cytidine shown in stick representation. The additional three carbons that comprise the methylpyrrole ring of pyrrolo-cytidine are colored green. The vcCNT-7C8C nucleo-pocket, formed mainly by G187 (TM4), V188 (TM4), and L259 (TM6), is delineated with a dotted line. The location of the cytoplasm, adjacent to the nucleo-pocket, is shown. For a stereo view of the electron density in the nucleoside-binding site, see Figure 5—figure supplement 1. (C) hCNT3 transports gemcitabine but not pyrrolo-gemcitabine. Na+ currents were elicited by the addition of nucleoside to Xenopus oocytes expressing hCNT3, and currents were measured by two-electrode voltage-clamp. An example current trace is shown. For each individual oocyte, the area under each current peak was measured to calculate total charge (Q) transported during application of nucleoside. The ratio of total charge co-transported with gemcitabine to that with pyrrolo-gemcitabine or gemcitabine total charge to gemcitabine + pyrrolo-gemcitabine total charge was calculated for each oocyte experiment (means ± SEM, n = 14 oocytes). For Gem + Pyr-Gem, 200 μM of each nucleoside was added simultaneously. (D) hCNT1 transports pyrrolo-gemcitabine better than gemcitabine. Same experiment as in C but hCNT1-expressing oocytes were used and the ratio of total charge for pyrrolo-gemcitabine to gemcitabine is shown (means ± SEM, n = 11 oocytes). Neither gemcitabine nor pyrrolo-gemcitabine elicited currents in water-injected oocytes (Figure 5—figure supplement 2) See Figure 5—source data 1 for total charge source data.DOI: http://dx.doi.org/10.7554/eLife.03604.02010.7554/eLife.03604.021Figure 5—source data 1. Total charge data.Total charge transported (μC) was calculated as the area under the curve of the current trace after application of the indicated nucleoside to hCNT-expressing Xenopus oocytes. Each row represents a separate experiment done using a different oocyte. The ratios of the total charge transported for the nucleosides are shown in the last columns.DOI: http://dx.doi.org/10.7554/eLife.03604.021Figure 5—figure supplement 1. Electron density at the nucleoside-binding site of vcCNT-7C8C-pyrrolo-cytidine.The nucleoside-binding site of vcCNT-7C8C bound to pyrrolo-cytidine is shown in stereo in stick representation in the same orientation and colored as the structures in Figure 2. Pyrrolo-cytidine is yellow, and the red spheres are water molecules. The resolution is 2.8 à and density shown is from a 2Fo–Fc electron density map contoured at 1σ.DOI: http://dx.doi.org/10.7554/eLife.03604.022
	Figure 5—figure supplement 2. Water-injected oocytes do not respond to gemcitabine or pyrrolo-gemcitabine treatment.Current traces are shown for three different oocyte experiments. Experiments were performed in the same manner as those in 5C and 5D except water-injected oocytes were used.DOI: http://dx.doi.org/10.7554/eLife.03604.023
	Figure 6. Structural basis of the subtype selectivity of pyrrolo-gemcitabine.(A) Model of hCNT3 nucleo-pocket. The structure of vcCNT-7C8C bound to pyrrolo-cytidine was used to generate a model of the hCNT3 nucleo-pocket by mutating the appropriate residues in PyMOL and selecting the rotamer that yielded the lowest amount of steric clash. (B) Model of hCNT1 nucleo-pocket. The model was generated in the same manner as A. Note that the methylpyrrole ring (green) will clash with the hCNT1 nucleo-pocket if it maintains the nucleoside-binding mode observed in the vcCNT structure. (C) Hypothetical alternating-access mechanism of vcCNT. A cartoon representation of the different conformational states along the transport cycle is depicted. The transport domain (including HP1, HP2, TM4b, and TM7b) and TM6 are shown as cylinders. Uridine is shown in stick representation. The nucleo-pocket in the inward-occluded conformation (bottom right) is located between TM6 and TM4 and is marked with a green star. The inward-occluded conformation is derived from the crystal structures of vcCNT. All other conformations are purely hypothetical. The transition between inward- and outward-facing conformations has been proposed to be achieved by a rigid-body movement of the transport domain across TM6 (Johnson et al., 2012). Extracellular and intracellular gating likely involves slight rearrangements of HP2/TM4b and HP1/TM7b, respectively. (D) hCNT3 (375L/446V) is capable of transporting both gemcitabine and pyrrolo-gemcitabine. Same experiment as Figure 5C,D but hCNT3 (375L/446V)-expressing oocytes were used and the ratio of total charge (Q) co-transported with gemcitabine to pyrrolo-gemcitabine is shown (means ± SEM, n = 11 oocytes). (E) hCNT1 (353V/424L) transports pyrrolo-gemcitabine less efficiently than gemcitabine (means ± SEM, n = 8 oocytes). Note that a higher nucleoside concentration was needed for D and E than the wild-type experiments due to lower transporter activity and/or expression. See Figure 6—source data 1 for total charge source data.DOI: http://dx.doi.org/10.7554/eLife.03604.02410.7554/eLife.03604.025Figure 6—source data 1. Total charge data.Total charge transported (μC) was calculated as the area under the curve of the current trace after application of the indicated nucleoside to hCNT-expressing Xenopus oocytes. Each row represents a separate experiment done using a different oocyte. The ratios of the total charge transported for the nucleosides are shown in the last columns.DOI: http://dx.doi.org/10.7554/eLife.03604.025

Baldwin, The equilibrative nucleoside transporter family, SLC29. 2004, Pubmed

Baldwin, The equilibrative nucleoside transporter family, SLC29. 2004, Pubmed
Bhutia, CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. 2011, Pubmed
Cano-Soldado, Functional analysis of the human concentrative nucleoside transporter-1 variant hCNT1S546P provides insight into the sodium-binding pocket. 2012, Pubmed
Choi, Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells. 2012, Pubmed
Clarke, The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine. 2006, Pubmed , Xenbase
Damaraju, Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. 2003, Pubmed
Damaraju, Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1. 2011, Pubmed , Xenbase
Damaraju, Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. 2012, Pubmed , Xenbase
Damaraju, Human nucleoside transporters: biomarkers for response to nucleoside drugs. 2009, Pubmed
Doehring, Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. 2011, Pubmed
Farré, Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. 2004, Pubmed
Fukao, Effect of genetic polymorphisms of SLC28A1, ABCG2, and ABCC4 on bioavailability of mizoribine in healthy Japanese males. 2011, Pubmed
Gao, Structure and mechanism of an amino acid antiporter. 2009, Pubmed
Graham, Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. 2000, Pubmed
Gray, Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. 2004, Pubmed , Xenbase
Gray, The concentrative nucleoside transporter family, SLC28. 2004, Pubmed
Hagenbuch, The SLCO (former SLC21) superfamily of transporters. 2013, Pubmed
Han, Targeted prodrug design to optimize drug delivery. 2000, Pubmed
He, Structure of a cation-bound multidrug and toxic compound extrusion transporter. 2010, Pubmed
Hu, Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. 2011, Pubmed
Johnson, Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å. 2012, Pubmed
Jordheim, Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. 2007, Pubmed
King, Nucleoside transporters: from scavengers to novel therapeutic targets. 2006, Pubmed
Koepsell, The SLC22 drug transporter family. 2004, Pubmed
Krishnamurthy, Unlocking the molecular secrets of sodium-coupled transporters. 2009, Pubmed
Lane, The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy. 2010, Pubmed
Loewen, Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na(+) nucleoside cotransporters hCNT1 and hCNT2. 1999, Pubmed , Xenbase
Mackey, Nucleoside transport and its significance for anticancer drug resistance. 1998, Pubmed
Majumdar, Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. 2004, Pubmed
Maréchal, Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. 2009, Pubmed
Molina-Arcas, Nucleoside transporter proteins. 2009, Pubmed
Monecke, Crystal structures of the novel cytosolic 5'-nucleotidase IIIB explain its preference for m7GMP. 2014, Pubmed
Naito, Impact of concentrative nucleoside transporter 1 gene polymorphism on oral bioavailability of mizoribine in stable kidney transplant recipients. 2010, Pubmed
Newstead, Crystal structure of a prokaryotic homologue of the mammalian oligopeptide-proton symporters, PepT1 and PepT2. 2011, Pubmed
Nishio, The CH/π hydrogen bond in chemistry. Conformation, supramolecules, optical resolution and interactions involving carbohydrates. 2011, Pubmed
Paproski, Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake. 2013, Pubmed , Xenbase
Pedersen, Crystal structure of a eukaryotic phosphate transporter. 2013, Pubmed
Pérez-Torras, Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. 2013, Pubmed
Quintiliani, Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTides. 2011, Pubmed
Rabascio, Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. 2010, Pubmed
Rau, Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection. 2013, Pubmed
Reyes, Transport mechanism of a bacterial homologue of glutamate transporters. 2009, Pubmed
Ringer, The effect of multiple substituents on sandwich and T-shaped pi-pi interactions. 2006, Pubmed
Rose, Physiology of nucleoside transporters: back to the future. . . 2008, Pubmed
Schlessinger, SLC classification: an update. 2013, Pubmed
Singh, Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. 2007, Pubmed
Slugoski, Conserved glutamate residues Glu-343 and Glu-519 provide mechanistic insights into cation/nucleoside cotransport by human concentrative nucleoside transporter hCNT3. 2009, Pubmed , Xenbase
Spratlin, The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. 2004, Pubmed
Suzuki, Structural basis for the specificity, catalysis, and regulation of human uridine-cytidine kinase. 2004, Pubmed
Wang, Structural basis for action by diverse antidepressants on biogenic amine transporters. 2013, Pubmed
Wang, An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. 1995, Pubmed
Waters, Aromatic interactions in model systems. 2002, Pubmed
Yao, Conserved glutamate residues are critically involved in Na+/nucleoside cotransport by human concentrative nucleoside transporter 1 (hCNT1). 2007, Pubmed , Xenbase
Zhang, Uridine binding and transportability determinants of human concentrative nucleoside transporters. 2005, Pubmed , Xenbase
Zhang, Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in Saccharomyces cerevisiae. 2003, Pubmed
Zhang, Studies of nucleoside transporters using novel autofluorescent nucleoside probes. 2006, Pubmed , Xenbase
Zhou, Structural basis of the alternating-access mechanism in a bile acid transporter. 2014, Pubmed